PPARA and metabolic dysfunction-associated steatotic liver disease: SCSIO41009, was found to reduce lipid accumulation by targeting LXRα and PPARα, two key regulators of lipid metabolism, in in vitro studies due to its unique bioactivity, and thus furazone has the potential to be a potent drug candidate for the treatment of NAFLD.